MLTX icon

MoonLake Immunotherapeutics
MLTX

Overview Fund Activity

118 hedge funds and large institutions have $3.21B invested in MoonLake Immunotherapeutics in 2023 Q3 according to their latest regulatory filings, with 47 funds opening new positions, 31 increasing their positions, 26 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
118
Holders Change
+35
Holders Change %
+42.17%
% of All Funds
1.88%
Holding in Top 10
10
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.16%
New
47
Increased
31
Reduced
26
Closed
11
Calls
$5.47M
Puts
$61.8M
Net Calls
-$56.3M
Net Calls Change
-$56.3M

Top Buyers

1
Adage Capital Partners
1
Adage Capital Partners
Massachusetts
$111M
2
TCM
2
TimesSquare Capital Management
New York
$23.4M
3
APM
3
Avidity Partners Management
Texas
$44.3M
4
SI
4
Sofinnova Investments
California
$16.7M
5
ACA
5
Avoro Capital Advisors
New York
$114M

Top Sellers

1
PCH
1
Polar Capital Holdings
United Kingdom
$53.5M
2
BPC
2
Banque Pictet & Cie
Switzerland
$0
3
AllianceBernstein
3
AllianceBernstein
Tennessee
$26.9M
4
AG
4
Artal Group
Luxembourg
$0
5
PBA
5
Paradigm Biocapital Advisors
New York
$0
Name Holding Trade Value Shares
Change 		Shares
Change %
Alyeska Investment Group
126
Alyeska Investment Group
Illinois
– -$2.92M -57,347 Closed
E
127
Ergoteles
New York
– -$1.97M -38,617 Closed
SC
128
Shay Capital
New York
– -$485K -9,500 Closed
Connor, Clark & Lunn Investment Management (CC&L)
129
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
– -$480K -9,421 Closed
2 3 4 5
6